GlassScriptPhysician profile
Deniz Baysal
NPI 1992772610
$464,449.43
in general payments reported to CMS, 2019-2025
16 companies · $1,526 in 2025
The $1,526 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151K · 2020: $38K · 2021: $68K · 2022: $86K · 2023: $75K · 2024: $45K · 2025: $1,526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $120K · Travel and Lodging: $1,246 · Food and Beverage: $648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $119,914.00 |
| Travel and Lodging | $1,246.45 |
| Food and Beverage | $648.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Central California Surgical Distributors, LLC | $461,292.00 | 2019-2024 | |
| Miach Orthopaedics, INC. | $1,431.45 | 2025 | |
| Baxter Healthcare | $341.19 | 2019 | |
| Smith+Nephew, INC. | $242.82 | 2019-2022 | |
| Boston Scientific Corporation | $240.13 | 2023-2025 | Wavewriter Alpha Prime 16, Infinion 16, Artisan |
| Zimmer Biomet Holdings, INC. | $155.01 | 2019-2021 | |
| Sanara Medtech INC. | $116.36 | 2023-2025 | Celleraterx, Celleraterx |
| Depuy Synthes Sales INC. | $115.73 | 2021 | |
| Medtronic, INC. | $114.68 | 2022-2024 | Aquamantys(Tm) |
| Stryker Corporation | $112.37 | 2022 | |
| Avanos Medical | $94.39 | 2019-2021 | |
| Abbott Laboratories | $65.35 | 2023 | Proclaim |
| Relievant Medsystems, INC. | $57.67 | 2021 | |
| Ethicon US, LLC | $46.04 | 2019-2022 | |
| Intrinsic Therapeutics | $24.24 | 2025 | Barricaid Acd (Annular Closure Device) |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$196,000.99 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deniz Baysal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.